Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGTCNASDAQ:ERYPNASDAQ:OTLKNASDAQ:TARA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/AERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AOTLKOutlook Therapeutics$8.20+1.4%$8.60$4.00▼$40.60$106.68M0.04537,698 shs151,652 shsTARAProtara Therapeutics$3.00-1.6%$3.76$1.04▼$5.24$34.29M1.71212,955 shs411,621 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%ERYPERYTECH Pharma0.00%0.00%0.00%-34.74%+241.71%OTLKOutlook Therapeutics+1.36%-6.29%-4.98%+2.50%-62.39%TARAProtara Therapeutics-1.64%+5.26%-25.37%+52.28%-16.43%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AOTLKOutlook Therapeutics3.0699 of 5 stars4.42.00.00.02.81.70.6TARAProtara Therapeutics2.0457 of 5 stars3.53.00.00.02.40.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTCApplied Genetic TechnologiesN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AOTLKOutlook Therapeutics2.88Moderate Buy$46.43466.16% UpsideTARAProtara Therapeutics3.00Buy$26.50783.33% UpsideCurrent Analyst RatingsLatest AGTC, ERYP, TARA, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024TARAProtara TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $30.004/8/2024TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.003/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/14/2024TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.002/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.001/25/2024OTLKOutlook TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$31.401/25/2024OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$40.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/ATARAProtara TherapeuticsN/AN/AN/AN/A$6.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/AERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AOTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)TARAProtara Therapeutics-$40.42M-$3.57N/AN/AN/AN/A-49.71%-43.82%5/2/2024 (Estimated)Latest AGTC, ERYP, TARA, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023TARAProtara Therapeutics-$1.03-$0.90+$0.13-$0.90N/AN/A2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTCApplied Genetic Technologies0.391.401.40ERYPERYTECH Pharma0.323.653.65OTLKOutlook TherapeuticsN/A0.440.44TARAProtara TherapeuticsN/A11.1711.17OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTCApplied Genetic Technologies22.05%ERYPERYTECH Pharma1.09%OTLKOutlook Therapeutics11.20%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipAGTCApplied Genetic Technologies4.10%ERYPERYTECH Pharma1.94%OTLKOutlook Therapeutics5.30%TARAProtara Therapeutics18.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableOTLKOutlook Therapeutics2413.01 million12.32 millionOptionableTARAProtara Therapeutics2611.43 million9.33 millionOptionableAGTC, ERYP, TARA, and OTLK HeadlinesSourceHeadlineProtara Therapeutics (NASDAQ:TARA) Given New $30.00 Price Target at Oppenheimeramericanbankingnews.com - April 23 at 3:26 AMProtara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54msn.com - April 17 at 12:11 PMProtara Therapeutics, Inc. (TARA)finance.yahoo.com - April 15 at 6:45 PMHere's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Nowzacks.com - April 12 at 10:56 AMBuy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatmentmarkets.businessinsider.com - April 9 at 2:25 AMProtara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equitymsn.com - April 5 at 3:10 PMProtara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline Chloridemarkets.businessinsider.com - April 5 at 10:10 AMProtara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock Upmarkets.businessinsider.com - April 5 at 10:10 AMProtara Therapeutics Announces Oversubscribed $45 Million Private Placement Financingglobenewswire.com - April 5 at 8:04 AMProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutritionglobenewswire.com - April 5 at 8:02 AMProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCglobenewswire.com - April 5 at 8:00 AM3 Stocks That Could Help You Retire on a Private Islandinvestorplace.com - March 23 at 6:00 AMBuy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunitymarkets.businessinsider.com - March 13 at 6:27 PMProtara Therapeutics: Q4 Earnings Snapshotchron.com - March 13 at 1:26 PMProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 13 at 8:00 AMTARA Aug 2024 7.500 callfinance.yahoo.com - March 3 at 11:42 PMTARA May 2024 2.500 putfinance.yahoo.com - March 3 at 11:42 PMNon Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024theglobeandmail.com - February 28 at 7:58 PMProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 28 at 8:00 AMNorthSea Therapeutics commences Phase IIa trial for IFALD therapymsn.com - February 22 at 7:53 PMWe're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Ratefinance.yahoo.com - February 17 at 8:43 AMCG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionalityseekingalpha.com - January 25 at 3:04 PMOppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)markets.businessinsider.com - December 2 at 7:37 PMProtara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncologyfinance.yahoo.com - November 30 at 12:38 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApplied Genetic TechnologiesNASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.ERYTECH PharmaNASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Protara TherapeuticsNASDAQ:TARAProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.